全身用药的眼部不良反应。
Adverse Ocular Effects of Systemic Medications.
作者信息
Green Michael B, Duker Jay S
机构信息
Department of Ophthalmology, Boston University School of Medicine, Boston, MA 02118, USA.
Department of Ophthalmology, New England Eye Center, Tufts Medical Center, Boston, MA 02111, USA.
出版信息
Life (Basel). 2023 Feb 28;13(3):660. doi: 10.3390/life13030660.
Abstract
While ocular complications of systemic medications are uncommon, it is important to recognize that vision-threatening toxicities can occur. This review details the vision-threatening adverse effects of a select group of commonly prescribed systemic medications and describes the recommended screening guidelines for those that are particularly high risk.
摘要
虽然全身性药物的眼部并发症并不常见，但认识到可能发生威胁视力的毒性反应很重要。本综述详细介绍了一组常用全身性药物的威胁视力的不良反应，并描述了针对那些特别高危药物的推荐筛查指南。
相似文献
1
Adverse Ocular Effects of Systemic Medications.
Life (Basel). 2023 Feb 28;13(3):660. doi: 10.3390/life13030660.
2
Ocular Side Effects of Common Systemic Medications and Systemic Side Effects of Ocular Medications.
Med Clin North Am. 2021 May;105(3):425-444. doi: 10.1016/j.mcna.2021.02.003.
3
Ocular complications of systemic medications.
Am J Med Sci. 2011 Jul;342(1):62-9. doi: 10.1097/MAJ.0b013e3181f06b21.
4
Ocular adverse effects of bladder medication: a systematic review.
Cutan Ocul Toxicol. 2022 Jun;41(2):129-136. doi: 10.1080/15569527.2022.2052889. Epub 2022 May 11.
5
Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1771-1781. doi: 10.1007/s00417-019-04337-8. Epub 2019 May 16.
6
[Adverse ocular effects to systemic drug therapy].
Orv Hetil. 2020 Jun;161(23):951-961. doi: 10.1556/650.2020.31723.
7
Drug-induced ocular disorders.
Drug Saf. 2008;31(2):127-41. doi: 10.2165/00002018-200831020-00003.
9
Ocular adverse effects associated with systemic medications : recognition and management.
Drugs. 2007;67(1):75-93. doi: 10.2165/00003495-200767010-00006.
10
Ocular toxicity of systemic medications: a case series.
Optometry. 2000 Jan;71(1):29-39.
引用本文的文献
1
Exploring comorbidity networks in mild traumatic brain injury subjects through graph theory: a traumatic brain injury model systems study.
BMC Neurol. 2025 Mar 7;25(1):94. doi: 10.1186/s12883-025-04102-x.
2
Assessing usability of electronic patient-reported outcome measures in older people with and without a rare dermatologic disorder.
J Patient Rep Outcomes. 2024 Dec 18;8(1):145. doi: 10.1186/s41687-024-00821-w.
本文引用的文献
1
Visual outcomes of toxic optic neuropathy secondary to Ethambutol: A retrospective observational study from India, an endemic country.
Indian J Ophthalmol. 2022 Sep;70(9):3388-3392. doi: 10.4103/ijo.IJO_2996_21.
2
Increased Incidence of Pseudotumor Cerebri Syndrome Among Users of Tetracycline Antibiotics.
J Neuroophthalmol. 2022 Sep 1;42(3):323-327. doi: 10.1097/WNO.0000000000001536. Epub 2022 Mar 25.
3
Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.
Indian J Ophthalmol. 2021 Dec;69(12):3734-3739. doi: 10.4103/ijo.IJO_3746_20.
4
Visual field defects after vigabatrin treatment during infancy: retrospective population-based study.
Dev Med Child Neurol. 2022 May;64(5):641-648. doi: 10.1111/dmcn.15099. Epub 2021 Oct 30.
5
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Arthritis Rheumatol. 2021 Jun;73(6):908-911. doi: 10.1002/art.41683. Epub 2021 Apr 26.
6
A Comparison Between the Clinical Features of Pseudotumor Cerebri Secondary to Tetracyclines and Idiopathic Intracranial Hypertension.
Am J Ophthalmol. 2020 Dec;220:177-182. doi: 10.1016/j.ajo.2020.07.037. Epub 2020 Jul 30.
7
Prevalence of Maculopathy Associated with Long-Term Pentosan Polysulfate Therapy.
Ophthalmology. 2020 Jun;127(6):835-836. doi: 10.1016/j.ophtha.2020.01.017. Epub 2020 Jan 17.
8
Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management.
Surv Ophthalmol. 2020 Jul-Aug;65(4):458-472. doi: 10.1016/j.survophthal.2020.01.002. Epub 2020 Feb 11.
9
Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis.
Can J Ophthalmol. 2020 Apr;55(2):116-125. doi: 10.1016/j.jcjo.2019.12.001. Epub 2020 Jan 20.
10
A review of systemic medications that may modulate the risk of glaucoma.
Eye (Lond). 2020 Jan;34(1):12-28. doi: 10.1038/s41433-019-0603-z. Epub 2019 Oct 8.
Zotero 插件